Skip to main content

Table 2 Association of Epidermal growth factor receptor (EGFR) expression with clinico-pathologic parameters of Endometrial carcinoma

From: Epidermal growth factor receptor (EGFR) overexpression in endometrial carcinoma: association with histopathologic parameters

  

n(%)

P-Value

Negative (n=65)

Low (n=19)

High (n=5)

Menopausal Status

Pre Menopausal

13 (20)

4 (21.1)

0 (0)

0.792

Post Menopausal

52 (80)

15 (78.9)

5 (100)

Histological Type

endometroid

60 (92.3)

14 (73.7)

3 (60)

0.009

serous

3 (4.6)

4 (21.1)

0 (0)

clear cell

1 (1.5)

0 (0)

0 (0)

carcinosarcoma

1 (1.5)

1 (5.3)

2 (40)

Grade

Grade I

28 (43.1)

6 (31.6)

1 (20)

0.055

Grade II

30 (46.2)

6 (31.6)

2 (40)

Grade III

7 (10.8)

7 (36.8)

2 (40)

Myometial Invasion

Limited To Endometrium

6 (9.2)

0 (0)

0 (0)

0.753

<1/2 Of Myometrium

23 (35.4)

6 (31.6)

2 (40)

>1/2 Of Myometrium

36 (55.4)

13 (68.4)

3 (60)

Cervical Invasion

Present

15 (23.1)

6 (31.6)

2 (40)

0.524

Absent

50 (76.9)

13 (68.4)

3 (60)

Nodal Status

N0

61 (93.8)

18 (94.7)

5 (100)

1.000

N1

3 (4.6)

1 (5.3)

0 (0)

N2

1 (1.5)

0 (0)

0 (0)

Lymphovascular Invasion

Present

3 (4.6)

3 (15.8)

0 (0)

0.278

Absent

62 (95.4)

16 (84.2)

5 (100)

T Stage

T1

47 (72.3)

13 (68.4)

62 (69.7)

0.094

T2

12 (18.5)

2 (10.5)

16 (18)

T3

4 (6.2)

4 (21.1)

8 (9)

T4

2 (3.1)

0 (0)

3 (3.4)

FIGO Stage

Stage IA

26 (40)

6 (31.6)

2 (40)

0.155

Stage IB

20 (30.8)

7 (36.8)

0 (0)

Stage II

13 (20)

2 (10.5)

2 (40)

Stage IIIA

4 (6.2)

3 (15.8)

0 (0)

Stage IIIB

0 (0)

1 (5.3)

0 (0)

Stage IV

2 (3.1)

0 (0)

1 (20)

Adnexal involvement

Present

5 (7.7)

3 (15.8)

1 (20)

0.321

Absent

60 (92.3)

16 (84.2)

4 (80)

  1. Fisher exact test applied
  2. P-value ≤ 0.05, considered as significant